Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942400 | 0.70 | ITGB3 (0.41) | DRD3GRIN1GRIN2BGRM5SIGMAR1 | |
| SCHEMBL4843429 | 0.68 | TRPV1 (0.36) | OPRM1 | |
| SCHEMBL7397950 | 0.68 | ALDH1A1 (0.52) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL6420268 | 0.67 | ITGB3 (0.56) | OPRM1 | |
| SCHEMBL6420263 | 0.67 | ITGB3 (0.56) | OPRM1 | |
| SCHEMBL3411465 | 0.66 | ESR1 (0.62) | — | |
| SCHEMBL11476415 | 0.66 | GRIN1 (0.60) | DRD3GRIN1GRIN2BGRM5SIGMAR1 | |
| SCHEMBL13738633 | 0.66 | ESR1 (0.50) | DRD3GRIN1GRIN2BSIGMAR1DRD1 | |
| SCHEMBL17951053 | 0.66 | ALDH1A1 (0.62) | ALDH1A1TSHRSMN1; SMN2SIGMAR1HTR2A | |
| SCHEMBL19974920 | 0.66 | ALDH1A1 (0.62) | ALDH1A1TSHRSMN1; SMN2SIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | DRD3 4315/4885GRIN1 1647/4885GRIN2B 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.